Aeschbach and Associates Inc is a licensed substance use treatment provider in Austin, TX, listed in the SAMHSA treatment directory. Outpatient care is offered, so clients can keep living at home between scheduled sessions. On site detox services are available, so withdrawal can be managed before treatment begins. Methadone is available as part of medication assisted treatment for opioid use disorder. Buprenorphine (Suboxone) is offered to reduce opioid cravings and lower relapse and overdose risk. Naltrexone is used to support recovery from opioid or alcohol use disorder. The program treats co-occurring mental health conditions alongside addiction. Private health insurance is accepted. It serves children/adolescents, young adults, adults.
Availability and current services change often. Call (888) 470-5244
and we will help you confirm openings, insurance, and next steps.
Levels of care
OutpatientOutpatient detoxificationOutpatient methadone/buprenorphine or naltrexone treatmentRegular outpatient treatment
Type of care
Substance use treatmentDetoxificationTreatment for co-occurring disorders plus serious emotional disturbance (SED) in children
Medications
Methadone used in TreatmentBuprenorphine used in TreatmentNaltrexone used in Treatment
Detox services
Alcohol DetoxificationBenzodiazepines DetoxificationOpioids detoxificationMedication routinely used during detoxification
Payment accepted
Federal, or any government funding for substance use treatment programsMedicareFederal military insurance (e.g., TRICARE)Private health insuranceCash or self-payment
Ages served
Children/AdolescentsYoung AdultsAdultsSeniors
Accreditation
State department of healthThe Joint CommissionSAMHSA certification for opioid treatment program (OTP)Drug Enforcement Agency (DEA)
Free & confidential, 24/7
Not sure which program fits? Talk it through with someone who can help.
1631 East 2nd Street, Building A, Austin, TX 78702
OutpatientOutpatient methadone/buprenorphine or naltrexone treatmentRegular outpatient treatmentFederal, or any government funding for substance use treatment programsMedicare